DICE Therapeutics (NASDAQ:DICE) Rating Increased to Hold at Zacks Investment Research

DICE Therapeutics (NASDAQ:DICEGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday, Zacks.com reports.

According to Zacks, “DICE Therapeutics Inc. is a biopharmaceutical company. Its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif. “

DICE Therapeutics stock traded down $0.65 during trading hours on Monday, reaching $17.05. The company had a trading volume of 269,417 shares, compared to its average volume of 327,925. The company has a debt-to-equity ratio of 0.01, a current ratio of 20.75 and a quick ratio of 20.75. The company has a 50-day moving average price of $18.97 and a 200 day moving average price of $21.22. DICE Therapeutics has a 12-month low of $13.39 and a 12-month high of $40.50.

DICE Therapeutics (NASDAQ:DICEGet Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.50) EPS for the quarter, hitting analysts’ consensus estimates of ($0.50). Analysts forecast that DICE Therapeutics will post -2.33 EPS for the current year.

Institutional investors have recently made changes to their positions in the business. Strs Ohio purchased a new position in DICE Therapeutics in the 4th quarter worth approximately $80,000. Suvretta Capital Management LLC purchased a new position in DICE Therapeutics in the 3rd quarter worth approximately $13,428,000. RA Capital Management L.P. purchased a new position in DICE Therapeutics in the 3rd quarter worth approximately $170,592,000. Janus Henderson Group PLC bought a new stake in shares of DICE Therapeutics in the 3rd quarter worth approximately $58,627,000. Finally, Tudor Investment Corp Et Al bought a new stake in shares of DICE Therapeutics in the 3rd quarter worth approximately $2,750,000. 82.91% of the stock is currently owned by institutional investors and hedge funds.

About DICE Therapeutics (Get Rating)

DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.

See Also

Get a free copy of the Zacks research report on DICE Therapeutics (DICE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.